PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 38 filers reported holding PROTAGONIST THERAPEUTICS INC in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $642,280 | +6.6% | 38,506 | +76.6% | 0.00% | – |
| Q2 2023 | $602,365 | -53.4% | 21,809 | -61.2% | 0.00% | -100.0% |
| Q1 2023 | $1,292,968 | +112.0% | 56,216 | +0.6% | 0.00% | – |
| Q4 2022 | $609,770 | +600.9% | 55,891 | +443.2% | 0.00% | – |
| Q3 2022 | $87,000 | -71.0% | 10,289 | -72.9% | 0.00% | – |
| Q2 2022 | $300,000 | -58.7% | 37,956 | +23.6% | 0.00% | – |
| Q1 2022 | $727,000 | -81.5% | 30,700 | -73.2% | 0.00% | -100.0% |
| Q4 2021 | $3,922,000 | +282.6% | 114,696 | +98.3% | 0.00% | – |
| Q3 2021 | $1,025,000 | +251.0% | 57,854 | +299.7% | 0.00% | – |
| Q4 2020 | $292,000 | +12.7% | 14,473 | +9.1% | 0.00% | – |
| Q3 2020 | $259,000 | +197.7% | 13,268 | +2.5% | 0.00% | – |
| Q2 2018 | $87,000 | -62.5% | 12,945 | +18.1% | 0.00% | -100.0% |
| Q3 2016 | $232,000 | – | 10,964 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $67,646,434 | 21.00% |
| COWEN AND COMPANY, LLC | 1,657,551 | $45,781,558 | 3.80% |
| Kynam Capital Management, LP | 975,298 | $26,937,731 | 3.70% |
| BVF INC/IL | 3,775,900 | $104,290,358 | 2.91% |
| RTW INVESTMENTS, LP | 5,415,514 | $149,576,497 | 2.85% |
| Cormorant Asset Management, LP | 1,500,000 | $41,430,000 | 2.32% |
| Ghost Tree Capital, LLC | 225,000 | $6,214,500 | 2.05% |
| 683 Capital Management, LLC | 814,000 | $22,482,680 | 1.62% |
| Perceptive Advisors | 1,469,761 | $40,594,799 | 1.18% |
| Artia Global Partners LP | 112,340 | $3,102,831 | 1.07% |